Dynavax Technologies Corporation (DVAX)
NASDAQ: DVAX · Real-Time Price · USD
10.64
+0.06 (0.57%)
Aug 13, 2025, 9:55 AM - Market open
Alteryx Revenue
Dynavax Technologies had revenue of $95.44M in the quarter ending June 30, 2025, with 29.33% growth. This brings the company's revenue in the last twelve months to $316.27M, up 26.66% year-over-year. In the year 2024, Dynavax Technologies had annual revenue of $277.25M with 19.36% growth.
Revenue (ttm)
$316.27M
Revenue Growth
+26.66%
P/S Ratio
4.21
Revenue / Employee
$780,909
Employees
405
Market Cap
1.25B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 277.25M | 44.96M | 19.36% |
Dec 31, 2023 | 232.28M | -490.40M | -67.86% |
Dec 31, 2022 | 722.68M | 283.24M | 64.45% |
Dec 31, 2021 | 439.44M | 399.19M | 991.75% |
Dec 31, 2020 | 40.25M | 5.03M | 14.29% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
DVAX News
- 2 days ago - Dynavax Technologies: A Dip To Accumulate - Seeking Alpha
- 5 days ago - Dynavax Technologies Corporation (DVAX) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 5 days ago - Dynavax Reports Second Quarter 2025 Financial Results - PRNewsWire
- 14 days ago - Dynavax to Report Second Quarter 2025 Financial Results and Host Conference Call on August 7, 2025 - PRNewsWire
- 2 months ago - Dynavax elects all four of its nominees after Deep Track proxy fight - Reuters
- 2 months ago - Dynavax Stockholders Elect All Dynavax Director Nominees at 2025 Annual Meeting - PRNewsWire
- 2 months ago - Deep Track Capital Sends Letter to Dynavax Technologies Shareholders Offering Final Perspectives on Why Change is Needed in the Boardroom - Business Wire
- 2 months ago - Dynavax Urges Stockholders to Support Its Director Nominees at June 11 Annual Meeting - PRNewsWire